There’s a lot going on and anticipated in the contract development and manufacturing segment including consolidation and some big ticket M&A, expanding growth opportunities given pharma’s continued appetite for outsourcing, and challenges posed by the supply squeeze for active pharmaceutical ingredients (APIs), intermediates and key starting materials with China clamping down on polluting industries.
Vivek Sharma, CEO of Piramal Pharma Solutions (PPS), which has been in the thick of some of the action, shared his views on a range of key sectoral issues in a freewheeling interview with